Sara Garcia Ptacek

Sara Garcia Ptacek

Biträdande Lektor | Docent
Besöksadress: Blickagången 16, 14152 Huddinge
Postadress: H1 Neurobiologi, vårdvetenskap och samhälle, H1 Klinisk geriatrik Garcia Ptacek, 171 77 Stockholm
Del av:

Om mig

  • Jag är gruppledare, biträdande lektor och neurologspecialist som arbetar med forskning och klinisk handläggning av kognitiva sjukdomar vid Karolinska Institutet och vid Kognitivmottagningen, Karolinska Universitetssjukhuset i Solna.
    Jag bedriver registerforskning med Svenska Demensregistret (SveDem), med fokus på faktorer som kan förbättra diagnostik, vård, behandling och utfall vid demens. Jag studerar också COVID, särskilt i relation till geriatriska populationer och kognitiva risker. Jag samarbetar med det europeiska konsortiet European Dementia with Lewy bodies (E-DLB).

    2023 Docent i neurovetenskap vid Karolinska Institutet, Sverige.
    2019 Fellow of the European Board of Neurology (FEBN)
    2017–2020: Postdoktoral forskning finansierad av Svenska Sällskapet för Medicinsk Forskning.
    2017 Pris för klinisk avhandling från Spanska Kungliga Nationella Medicinakademien.
    2015 Pris för framstående doktorsavhandling från Universidad Complutense de Madrid.
    2015 Doktorsavhandling. "Demens: prekliniska stadier och mortalitet i svenska kohorter". Universidad Complutense de Madrid, Spanien. Handledare: Maria Luz Cuadrado (Universidad Complutense de Madrid – handledare och avhandlingsföreståndare) och Maria Eriksdotter (Karolinska Institutet – avhandlingsföreståndare). Avhandlingen tilldelades Cum Laude och European Mention.

    https://eprints.ucm.es/34377/1/T36508.pdf [1]
    [1] https://eprints.ucm.es/34377/1/T36508.pdf

Forskningsbeskrivning

  • *Medication repurposing to slow cognitive decline in dementia:*
    Medication repurposing is a cost and time-effective way to discover new
    treatments. Swedish registers are a unique tool to detect medication
    candidates for repurposing. The Swedish Dementia Registry (SveDem
    www.svedem.se) has >100000 patients and repeated measures of cognition over
    time (measured with the Mini-Mental State Examination—MMSE), making it
    perfect to examine whether certain medications are associated with less
    cognitive decline in patients with dementia. We propose a study combining
    traditional cohort studies and newer artificial intelligence (machine
    learning) techniques to detect medications associated with slower cognitive
    decline in patients from SveDem. We will test pre-specified hypotheses since
    we suspect specific medications are better candidates to prevent cognitive
    decline, but we will also let the machine learning algorithms explore the
    data to find associations that we do not suspect in advance. Finally, the
    candidate medications will be tested in animal and cellular models to
    determine the mechanisms of their effects.
    *Influence of COVID-19 and the pandemic on care, treatment and cognition of
    persons with dementia in Sweden:*
    The Covid-19 pandemic has impacted the health and livelihood of most people
    worldwide but has disproportionately affected individuals in disadvantaged
    positions. We aim to examine the incidence and consequences of Covid-19 and
    the greater consequences of the pandemic in individuals with dementia. We
    identified individuals with Covid-19 from SmiNet and age, sex and region
    matched controls. Merged registries provided information on socioeconomic
    position in the years before and after Covid-19, social support and care,
    medications, dementia diagnosis and other comorbidities and mortality.
    Because Covid-19 disrupts care in patients with dementia, we use the Swedish
    Dementia Registry (SveDem), to determine how patients with dementia,
    specifically, fared during the pandemic. At present, we are have obtained
    this dataset and are actively seeking funding for this project.

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Medication repurposing in dementia: selecting brain-friendly medications and establishing a new indication
    Centrum för Innovativ Medicin
    1 January 2026 - 31 December 2028
  • Medication repurposing to slow cognitive decline in Alzheimer's dementia
    ALF Medicin-Region Stockholm
    1 January 2026 - 31 December 2028
  • Neuroprotection with Repurposed Cardiovascular Drugs in Alzheimer's Disease
    Alzheimerfonden
    1 January 2025 - 31 December 2025
  • Nya innovativa vägar mot Alzheimers sjukdom: Vätskebiomarkörer och intracellulära behandlingar
    Private donation from Leif Lundblad Family and others
    1 October 2023 - 30 September 2026
  • Translationell identifiering av läkemedel för behandling av Alzheimersdemens
    Vetenskapsrådet
    1 January 2023 - 1 January 2026
  • Biomarkers and Intracellular treatments
    New Innovative Ways to Treat Alzheimer—Leif Lundblad and others-project
    1 January 2023 - 30 September 2025
  • Causal inference using Dynamic Bayesian Networks to find medications related to slow cognitive decline in dementia: Studies from the Swedish Dementia Registry
    Loo and Hans Osterman Foundation 2022
    1 July 2022 - 1 July 2023

Anställningar

  • Biträdande Lektor, Neurobiologi, vårdvetenskap och samhälle, Karolinska Institutet, 2021-2027

Examina och utbildning

  • Docent, Neurovetenskap, Karolinska Institutet, 2023

Nyheter från KI

Kalenderhändelser från KI